IMPROVEMENTS IN OR RELATING TO THE PROTECTION OF DOMESTIC ANIMALS AGAINST PATHOGENIC ORGANISMS

... 1,234,747. Brucella vaccines. PHILIPS ROXANE Inc. 20 Feb., 1969 [23 Feb., 1968], No. 9179/69. Heading A5B. A method of protecting a non-borine domestic mammal, excluding rodents, susceptible to attack by a virulent pathogen of the genus Brucella, comprises inoculating the mammal with a small but effective amount of a vaccine comprised of inactivated or killed borine Brucella abortus.

STREPTOKOKKEN-C5A-PEPTIDASE-IMPFSTOFF

USES A BORRELIAZIDEN OF A EPITOPS OF THE AUSSERMEMBRANPROTEINS C OF BORRELIA BURGDORFERI (OSPC) AS IMPSTOFF

STREPTOKOKKEN-C5A-PEPTIDASE-IMPFSTOFF

Immunological combination compositions and methods

USES OF THE BORRELIACIDAL EPITOPE(S) OF BORRELIA BURGDORFERI OUTER SURFACE PROTEIN C (OSPC) AS VACCINE

An OspC Dra fragment fusion peptide isolated from Borrelia burgdorferi is described herein for the prevention, treatment and early diagnosis of Lyme disease in humans and other animals. This invention also relates to a screening method detecting anti-Osp borreliacidal antibody activity, and antibodies reacting with a protein fragment encoded by a DraI-SmaI DNA fragment of OspC.

IMMUNIZING COMPOSITIONS AND METHODS OF USE

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods making and methods of using such compositions.

USE OF OPRI LIPOPROTEIN FROM PSEUDOMONAS AS A TH1 INDUCING NATURAL ADJUVANT FOR HETEROLOGOUS ANTIGENS

The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of Oprl - antigen fusion proteins to elicit said Typ-1 response. More particurarly, the present invention is directed to pharmaceutical formulations comprising Oprl and/or Oprl fusion proteins, optionnaly together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.

Canine coronavirus vaccine from feline enteric coronavirus

This invention provides a vaccine which contains, per dose, an effective immunizing amount of an inactivated feline enteric coronavirus and a suitable carrier. The vaccine of this invention may also contain an adjuvant, an effective immunizing amount of a second inactivated virus and a an effective immunizing amount of an inactivated bacteria. Additionally provided by this invention is a method of immunizing a dog against disease caused by canine coronavirus involving administering to the dog a dose of the vaccine of this invention. The method of this invention may also involve administering one or more additional doses of vaccine to the dog, immunizing the dog against disease caused by a second virus and immunizing the dog against disease caused by a bacteria.

Methods for treating high somatic cell counts

The present invention provides methods for treating an animal having a high somatic cell count. The methods include administering compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter.

COMBINATION COMPOSITIONS FOR THE LYME ILLNESS AND APPLICATIONS

IMMUNOLOGICAL COMBINATION MEANS AND PERTINENT ONE PROCEDURE

Streptococcal c5a peptidase vaccine

Vaccines and methods to treat canine influenza

Lyme combination compositions and uses

IMMUNIZING COMPOSITIONS AND METHODS OF USE

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Streptococcal c5a peptidase vaccine

本发明提供了一种用于抗β－溶血链球菌集群或感染的新型疫苗。这种疫苗包含一种具有免疫原量的链球菌C5a肽酶的突变体(SCP)，同时也提供了一种通过使用此种疫苗保护易感的哺乳动物抗β－溶血链球菌集群或感染的方法，并对无酶活性的SCP和编码SCP蛋白多聚核糖核基酸也进行了披露。

VACCINES AND METHODS TO TREAT CANINE INFLUENZA

The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. The invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.

Bacterial preparations, method for producing same, and their use as vaccines

Novel bacterial preparations containing one or more isolated and purified strain of a microorganism which produces one or more RTX toxins, and which strain has at least one RTX toxin which is substantially cell-associated. Methods of preparing the bacterial preparations and their use as vaccines and to produce antibodies for passive immunization are described.

ВАКЦИНЫ И СПОСОБЫ ЛЕЧЕНИЯ СОБАЧЬЕГО ГРИППА

FIELD: medicine. ^ SUBSTANCE: present invention refers to production of new vaccines and methods of treating the diseases associated with canine influenza virus. The method of immunisation of a dog against influenza virus involves introduction to a specified dog of a therapeutically effective amount of the vaccine containing at least one attenuated or inactivated H3N8 influenza virus where the specified virus is recovered from a dog, and the amount of the specified virus is 10 to 10000 GA units, and the vaccine additionally contains an adjuvant where the adjuvant can be chosen from the metabolised adjuvant, b) the non-metabolised adjuvant, c) 2% alum, d) 5% alum, e) Quil A, and f) cholesterol or any combination thereof. The method for preparing the vaccine against canine influenza virus includes making the composition containing the therapeutically effective amount of at least one attenuated or inactivated H3N8 influenza virus where the specified virus is recovered from a dog. Application of the vaccine prepared by the method for immunisation of dogs against influenza virus. ^ EFFECT: invention provides higher immunisation effectiveness. ^ 12 cl, 7 tbl РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 396 976 (13) C2 (51) МПК A61K 39/145 (2006.01) A61P 31/12 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (30) Конвенционный приоритет: 07.10.2005 US 60/724,827 (73) Патентообладатель(и): ПФАЙЗЕР ПРОДАКТС ИНК. (US) (43) Дата публикации заявки: 10.10.2009 C 2 2 3 9 6 9 7 6 (85) Дата перевода заявки PCT на национальную фазу: 04.04.2008 (86) Заявка PCT: IB 2006/002741 (25.09.2006) R U C 2 (56) Список документов, цитированных в отчете о поиске: WO 0009702 A1, 24.02.2000. WOOD J. M. et al. The standardization of inactivated equine influenza vaccines by single-radial immunodiffusion. Journal of biological standardization. Apr. 1983, vol.11, no.2, April 1983 (1983-04), p.133-136. ENSERINK MARTIN Epidemiology. ...

BORRELIA BURGDORFERI BACTERIN

USE OF OPRI LIPOPROTEIN OUT PSEUDOMONAS AS TH1 INDUCING NATURAL ADJUVANS FOR HETEROLOGE ANTIGENS

STREPTOCOCCAL C5A PEPTIDASE VACCINE

Novel vaccines for use against .beta.-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against .beta.-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.

BORRELIA BURGDORFERI BACTERIN

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first Borrelia burgdorferi isolate and a second, non-crossprotective Borrelia burgdorferi isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third Borrelia burgdorferi. Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi and one or more antigenic subunits from the non-crossprotective isolates, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi and antigenic subunits and a suitable carrier. Methods of immunizing an animal against Borrelia burgdorferi infection which comprise administering to the animal a dose of a bacterin provided herein are also provided.

LYME DISEASE ANTIGEN COMPOSITIONS AND USES

Disclosed and claimed are compositions containing a Borrelia burgdorferi antigen, and methods for making and using them. The antigen can be OspA. The compositions can contain at least one additional antigen from a pathogen other than Borrelia burgdorferi. The compositions are useful for eliciting an immunological response in a host mammal susceptible to Lyme Disease and to the mammalian pathogen other than Borrelia burgdorferi. Suitable host mammals include dogs, pups, horses, and, the additional antigen can be of a canine, equine or feline pathogen, such as rabies, canine distemper, adenovirus, coronavirus, parainfluenza and parvovirus. No significant efficacy interference is observed.

Immunogenic hybrid protein OprF-OprI derived from Pseudomonas aeruginosa membrane proteins

The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

Streptococcus C5a peptidase vaccine

Immunogenes Hybridprotein OprF-Oprl erhältlich aus Membranproteinen von Pseudomonas aeruginosa

Verfahren zum Schuetzen von Haustieren

COMPOSITIONS TO IMMUNISIERUNG AS WELL AS THEIR USE

IMMUNOGEN HYBRID PROTEIN OPRF OPRL AVAILABLE FROM DIAPHRAGM PROTEINS OF PSEUDOMONAS AERUGINOSA

Streptococcal C5a peptidase vaccine

USES OF THE BORRELIACIDAL EPITOPE(S) OF BORRELIA BURGDORFERI OUTER SURFACE PROTEIN C (OSPC) AS VACCINE

An OspC Dra fragment fusion peptide isolated from Borrelia burgdorferi is described herein for the prevention, treatment and early diagnosis of Lyme disease in humans and other animals. This invention also relates to a screening method detecting anti-Osp borreliacidal antibody activity, and antibodies reacting with a protein fragment encoded by a DraI-SmaI DNA fragment of OspC.

BORRELIA BURGDORFERI BACTERIN

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first Borrelia burgdorferi isolate and a second, non-crossprotective Borrelia burgdorferi isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third Borrelia burgdorferi. Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi and one or more antigenic subunits from the non-crossprotective isolates, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi and antigenic subunits and a suitable carrier. Methods of immunizing an animal against Borrelia burgdorferi infection which comprise administering to the animal a dose of a bacterin provided herein are also provided.

LYME COMBINATION COMPOSITIONS AND USES

Disclosed and claimed are compositions containing a Borrelia burgdorferi antigen, and methods for making and using them. The antigen can be OspA. The compositions can contain at least one additional antigen from a pathogen other than Borrelia burgdorferi. The compositions are useful for eliciting an immunological response in a host mammal susceptible to Lyme Disease and to the mammalian pathogen other than Borrelia burgdorferi. Suitable host mammals include dogs, pups, horses, and, the additional antigen can be of a canine, equine or feline pathogen, such as rabies, canine distemper, adenovirus, coronavirus, parainfluenza and parvovirus. No significant efficacy interference is observed.

BORRELIA BURGDORFERI BACTERIN

ZUSAMMENSETZUNGEN ZUR IMMUNISIERUNG SOWIE DEREN VERWENDUNG

IMMUNIZING COMPOSITIONS AND METHODS OF USE

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

TH1 inducing natural adjuvant for heterologous antigens

USE OF OPRI LIPOPROTEIN FROM PSEUDOMONAS AS A TH1 INDUCING NATURAL ADJUVANT FOR HETEROLOGOUS ANTIGENS

The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of Oprl - antigen fusion proteins to elicit said Typ-1 response. More particurarly, the present invention is directed to pharmaceutical formulations comprising Oprl and/or Oprl fusion proteins, optionnaly together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.

INTRA-RESPIRATORY VACCINE FOR PREVENTION OF BORDETELLA BRONCHISEPTICA INFECTION AND METHOD OF USE

IMMUNOLOGICAL COMBINATION COMPOSITIONS AND METHODS

Immunological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.

Polypeptides obtained from gram negative microbes

The present invention provides compositions including at least two siderophore receptor polypeptides and at least two porins from a gram negative microbe, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of makino and methods of using such compositions.

Streptococcal C5a peptidase vaccine

Lyme combination compositions and uses

IMMUNOGENIC HYBRID PROTEIN OPRF-OPRL DERIVED FROM PSEUDOMONAS AERUGINOSA MEMBRANE PROTEINS

The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and, the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

IMMUNIZING COMPOSITIONS AND METHODS OF USE

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods making and methods of using such compositions.

VACCINES AND METHODS TO TREAT CANINE INFLUENZA

The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. The invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.

IMMUNOLOGISCHE KOMBINATIONSMITTEL UND DAZUGEHÖRIGE VERFAHREN

Immunizing compositions and methods of use

COMPOSITIONS INCLUDING GRAM NEGATIVE SIDEROPHORE RECEPTOR PROTEINS AND METHODS OF USE

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

IMMUNOGENIC HYBRID PROTEIN OPRF-OPRL DERIVED FROM PSEUDOMONAS AERUGINOSA MEMBRANE PROTEINS

The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and, the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

BACTERIAL PREPARATIONS, METHOD FOR PRODUCING SAME, AND THEIRUSE AS VACCINES

Novel bacterial preparations containing one or more isolated and purified strain of a microorganism which produces one or more RTX toxins, and which strain has at least one RTX toxin which is substantially cell-associated. Methods of preparing the bacterial preparations and their use as vaccines and to produce antibodies for passive immunization are described.

ZUSAMMENSETZUNGEN ZUR IMMUNISIERUNG SOWIE DEREN VERWENDUNG

Vaccines and methods to treat canine influenza

Immunogenic hybrid protein OprF-OprL derived from Pseudomonas aeruginosa membrane proteins

STREPTOCOCCAL C5A PEPTIDASE VACCINE

Novel vaccines for use against .beta.-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against .beta.-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.

INTRA-RESPIRATORY VACCINE FOR PREVENTION OF BORDETELLA BRONCHISEPTICA INFECTION AND METHOD OF USE

INTRA-RESPIRATORY VACCINE FOR PREVENTION OF BORDETELLA BRONCHISEPTICA INFECTION AND METHOD OF USE A vaccine for animals subject to Bordetella bronchiseptica infection comprises an aqueous suspension of viable cells of the modified Bordetella bronchiseptica previously identified as strain 55 and now further identified as ATCC strain No. 31437. Strain 55 is not merely attenuated and avirulent but has been modified so that it will colonize the respiratory mucosa of animals for only a limited time before it is cleared, causing no adverse efrect on the animals. During the limited period of growth on the respiratory mucosa, however, strain 55 is capable of inducing local resistance to B. bronchiseptica infection. Swine are thereby protected against atrophic rhinitis and turbinate atrophy and dogs against tracheobronchitis (kennel cough).

Lyme combination compositions and uses

Disclosed and claimed are compositions containing a Borrelia burgdorferi antigen, and methods for making and using them. The antigen can be OspA. The compositions can contain at least one additional antigen from a pathogen other than Borrelia burgdorferi. The compositions are useful for eliciting an immunological response in a host mammal susceptible to Lyme Disease and to the mammalian pathogen other than Borrelia burgdorferi. Suitable host mammals include dogs, pups, horses, and, the additional antigen can be of a canine, equine or feline pathogen, such as rabies, canine distemper, adenovirus, coronavirus, parainfluenza and parvovirus. No significant efficacy interference is observed.

Streptococcal C5a peptidase vaccine

BORRELIA BURGDORFERI BACTERIN

LYME COMBINATION COMPOSITIONS AND USES

Disclosed and claimed are compositions containing a Borrelia burgdorferi antigen, and methods for making and using them. The antigen can be OspA. The compositions can contain at least one additional antigen from a pathogen other than Borrelia burgdorferi. The compositions are useful for eliciting an immunological response in a host mammal susceptible to Lyme Disease and to the mammalian pathogen other than Borrelia burgdorferi. Suitable host mammals include dogs, pups, horses, and, the additional antigen can be of a canine, equine or feline pathogen, such as rabies, canine distemper, adenovirus, coronavirus, parainfluenza and parvovirus. No significant efficacy interference is observed.

VERWENDUNGEN EINES BORRELIAZIDEN EPITOPS DES AUSSERMEMBRANPROTEINS C VON BORRELIA BURGDORFERI (OSPC) ALS IMPSTOFF

Streptococcal C5a peptidase vaccine

VACCINES AND METHODS TO TREAT CANINE INFLUENZA

The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. The invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses. © KIPO & WIPO 2008 ...

VACCINES AND PROCEDURES TO TREAT THE CANINE INFLUENZA

La presente se refiere a proporcionar vacunas y tratamientos para las enfermedades relacionadas con virus de la gripe canina. Describe antígenos virales de gripe, y procedimientos para presentar estos antígenos a canes, especialmente perros. se refiere a vacunas muertas y atenuadas. La presente se refiere a virus de la gripo canina y equina generados experimentalmente. También incluye gripe A, incluyendo H3, N8, H3N8, H7N7 y virus que contienen al menos un segmento del genoma de virus de la gripe canina o equina. La presente también se refiere al uso de estos virus en composiciones terapéuticas para proteger canes, perros en particular, de enfermedades causadas por virus de la gripe. Reivindicacion 1: Un procedimiento para inmunizar perros contra virus de la gripe, comprendiendo el procedimiento administrar a un perro una cantidad terapéuticamente eficaz de una vacuna que contiene al menos un virus de la gripe atenuado o muerto.

Method of vaccination for prevention of Bordetella bronchiseptica infection

Viable cells of an avirulent self-clearing strain of B. bronchiseptica are administered as an intra-respiratory vaccine. An aqueous suspension of the cells is applied to the respiratory mucosa immediately after incorporating a non-inhibitory amount of a wetting agent promoting the mucosal implantation of the cells. Effective immunization can thereby be obtained against diseases such as kennel cough in dogs and atrophic rhinitis in swine even through the strain of B. bronchiseptica is so highly attenuated that it is self-clearing from the respiratory mucosa.

Streptococcal C5a peptidase vaccine

Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.

KOMBINATIONSZUSAMMENSETZUNGEN FÜR DIE LYME-ERKRANKUNG UND ANWENDUNGEN

vacina para peptidase c5a estreptocócica

BORRELIA BURGDORFERI BACTERIN

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first Borrelia burgdorferi isolate and a second, non-crossprotective Borrelia burgdorferi isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third Borrelia burgdorferi. Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi and one or more antigenic subunits from the non-crossprotective isolates ...

Borrelia burgdorferi bacterin

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first Borrelia burgdorferi isolate and a second, non-crossprotective Borrelia burgdorferi isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third Borrelia burgdorferi. Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi and one or more antigenic subunits from the non-crossprotective isolates ...

Streptococcal C5a peptidase vaccine

Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens

Immunizing compositions and methods of use

TH1 INDUCING NATURAL ADJUVANT FOR HETEROLOGOUS ANTIGENS

The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of Oprl - antigen fusion proteins to elicit said Typ-1 response. More particurarly, the present invention is directed to pharmaceutical formulations comprising Oprl and/or Oprl fusion proteins, optionnaly together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.

Cholera toxin chimera and its use as a staph vaccine

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.

Intra-respiratory vaccine for prevention of Bordetella bronchiseptica infection and method of use

A vaccine for animals subject to Bordetella bronchiseptica infection comprises an aqueous suspension of viable cells of the modified Bordetella bronchiseptica previously identified as strain 55 and now further identified as ATCC strain No. 31437. Strain 55 is not merely attenuated and avirulent but has been modified so that it will colonize the respiratory mucosa of animals for only a limited time before it is cleared, causing no adverse effect on the animals. During the limited period of growth on the respiratory mucosa, however, strain 55 is capable of inducing local resistance to B. bronchiseptica infection. Swine are thereby protected against atrophic rhinitis and turbinate atrophy and dogs against tracheobronchitis (kennel cough).

Immunizing compositions and methods of use

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine

Streptococcal C5a peptidase vaccine

Methods for detecting antibody that specifically bind a siderophore receptor polypeptide

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Immunological combination compositions and methods

VACCINES AND METHODS TO TREAT CANINE INFLUENZA

Immunizing compositions and methods of use

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Methods for making compositions including gram negative microbial polypeptides

The present invention provides methods for making compositions including siderophore receptor polypeptides and porins from gram negative microbes. The methods include providing a gram negative microbe, disrupting the microbe, solubilizing the disrupted microbe, and isolating the polypeptides.

IMMUNOLOGISCHE KOMBINATIONSMITTEL UND DAZUGEHÖRIGE VERFAHREN

Streptokokken-C5a-Peptidase-Impfstoff

Vaccines and methods to treat canine influenza

The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza vaccines and viruses. The invention also includes influenza A, H3, N8, H3N8, and H7N7 viruses which contain at least one genome segment from a canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.

Compositions of immunization and methods of use

COMPOSITIONS IMUNIZANTES AND METHODS OF USE

Vaccines and methods to treat canine influenza

The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. The invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.

PROTECTING DOGS AGAINST BRUCELLA CANIS BACTEREMIA WITH KILLED BRUCELLA ABORTUS STRAIN 45/20 VACCINE

-i(BORRELIA BURGDORFERI) BACTERIN

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first Borrelia burgdorferi isolate and a second, non-crossprotective Borrelia burgdorferi isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third Borrelia burgdorferi. Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi and one or more antigenic subunits from the non-crossprotective isolates ...

Sterilization process for mammals

Aspermatogenesis is achieved in mammalian species without disturbance of libido and hormone level by intratesticular injection of Bacillus of Calmette and Guerin. The procedure is applicable to a wide variety of mammalian species.

Streptococcal C5a peptidase vaccine

Novel vaccines for use against beta -hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against beta -hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.

LYME COMBINATION COMPOSITIONS AND USES

IMMUNOLOGICAL COMBINATION COMPOSITIONS AND METHODS

Borrelia burgdorferi bacterin

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi , an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first Borrelia burgdorferi isolate and a second, non-crossprotective Borrelia burgdorferi isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third Borrelia burgdorferi . Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi and one or more antigenic subunits from the non-crossprotective isolates, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi and antigenic subunits and a suitable carrier.

Cholera toxin chimera and its use as a staph vaccine

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus . One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus -specific polypeptide.

Streptococcal C5a peptidase vaccine

Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.

Methods for treating mastitis in a milk producing animal

The present invention provides methods for treating mastitis in a milk producing animal. The methods include administering compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter.

Immunizing compositions and methods of use

The present invention provides compositions including antibodies that specifically bind at least one siderophore receptor polypeptide from a gram positive microbe. The present invention also provides methods of making and methods of using such compositions.

Combined immunological compositions and their use

Immunological combination compositions and methods

Immunological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.

Immunization preparations and their use

Immunogenic Hybrid Protein OprF-Oprl Derived from Pseudomonas aeruginosa Membrane Protein

본 발명은 슈도모나스 에루지노사 외막 단백질 F(OprF)의 카복시-말단 부분의 카복시 말단 끝에 그의 아미노 말단이 융합된 슈도모나스 에루지노사 외막 단백질 I(OprI)를 포함하는 하이브리드 단백질 및 상기 하이브리드 단백질에 대한 모노클로날 또는 폴리클로날 항체에 관한 것이다. 단백질 및 하이브리드 단백질 및 하이브리드 단백질에 대한 항체 모두는 실험 동물 또는 사람을 슈도모나스 에루지노사 감염으로부터 보호한다.

Vaccines and methods for treating canine influenza

Borrelia Burgdorferi bacterium

Immunogenic hybrid protein OprF-Oprl available from membrane proteins from Pseudomonas aeruginosa

Lyme combination compositions and uses

Disclosed and claimed are compositions containing a Borrelia burgdorferi antigen, and methods for making and using them. The antigen can be OspA. The compositions can contain at least one additional antigen from a pathogen other than Borrelia burgdorferi. The compositions are useful for eliciting an immunological response in a host mammal susceptible to Lyme Disease and to the mammalian pathogen other than Borrelia burgdorferi. Suitable host mammals include dogs, pups, horses, and, the additional antigen can be of a canine, equine or feline pathogen, such as rabies, canine distemper, adenovirus, coronavirus, parainfluenza and parvovirus. No significant efficacy interference is observed.

Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins

The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens

The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of Oprl - antigen fusion proteins to elicit said Typ-1 response. More particurarly, the present invention is directed to pharmaceutical formulations comprising Oprl and/or Oprl fusion proteins, optionnaly together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.

Immunizing compositions and methods of use

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Bordetella Bronchiseptica vaccine

A vaccine for protecting canines against infection by Bordetella bronchiseptica is prepared by inactivating whole cells with glutaraldehyde.

Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins

The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

Immunological combination compositions and methods

Immununological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.

Streptococcal C5A peptidase vaccine

Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.

Use of Borrelia buldaridal epitope of Borrelia burgdorferi external surface protein C (OSPC) as vaccine

Immunizing compositions and methods of use

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Συνθεσεις ανοσοποιησης και μεθοδοι χρησης

Η παρούσα εφεύρεση παρέχει συνθέσεις που περιλαμβάνουν πολυπεπτιδικούς υποδοχείς σιδηροφόρων και πορίνες από gram αρνητικά μικρόβια, και κατά προτίμηση, λιποπολυσακχαρίτη σε συγκέντρωση όχι μεγαλύτερη από αυτή περίπου των 10,0 μονάδων ενδοτοξίνης ανά χιλιοστό του λίτρου. Η παρούσα εφεύρεση επίσης παρέχει μεθόδους κατασκευής και μεθόδους χρήσης τέτοιων συνθέσεων.

Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene

Streptokokken-c5a-peptidase-impfstoff

Streptokokken-c5a-peptidase-impfstoff

Immunologische kombinationsmittel und dazugehörige verfahren

Cholera Toxin Chimera and its Use as a Staph Vaccine

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of an antigenic material from S. aureus and an antigenic material from a S. aureus -specific polypeptide.

Cholera toxin chimera and its use as a staph vaccine

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.

Cholera toxin chimera and its use as a staph vaccine

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus . One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus -specific polypeptide.

Cholera toxin chimera and its use as a staph vaccine

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus . One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus -specific polypeptide.

Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff

Cholera toxin chimera and its use as a staph vaccine

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus . One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus -specific polypeptide.

Zusammensetzungen zur immunisierung sowie deren verwendung

Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine

Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff

Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine

Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine

An OspC Dra fragment fusion peptide isolated from Borrelia burgdorferi is described herein for the prevention, treatment and early diagnosis of Lyme disease in humans and other animals. This invention also relates to a screening method detecting anti-Osp borreliacidal antibody activity, and antibodies reacting with a protein fragment encoded by a DraI-SmaI DNA fragment of OspC.

Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine

Borrelia burgdorferi bacterin

Kombinationszusammensetzungen für die lyme- erkrankung und anwendungen

호흡기내 백신 제조방법

내용 없음

Intra-respiratory vaccine for prevention of bordetella bronchiseptica infection and method of use

Cholera toxin chimera and its use as a staph vaccine

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus . One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus -specific polypeptide.

Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa

链球菌C5a肽酶疫苗

本发明提供了一种用于抗β-溶血链球菌集群或感染的新型疫苗。这种疫苗包含一种具有免疫原量的链球菌C5a肽酶的突变体(SCP)，同时也提供了一种通过使用此种疫苗保护易感的哺乳动物抗β-溶血链球菌集群或感染的方法，并对无酶活性的SCP和编码SCP蛋白多聚核糖核基酸也进行了披露。

[UNK]